1 Min Read
May 17 (Reuters) - Kaken Pharmaceutical Co Ltd :
* Says product Jublia, topical formulation for Onychomycosis, has received marketing approval in South Korea
Source text in Japanese: goo.gl/bq6tyA
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.